中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
11期
990-992,993
,共4页
恩替卡韦分散片%恩替卡韦片%乙型病毒性肝炎%肝硬化
恩替卡韋分散片%恩替卡韋片%乙型病毒性肝炎%肝硬化
은체잡위분산편%은체잡위편%을형병독성간염%간경화
Entecavir dispersible tablets%Entecavir tablets%Hepatitis B%Liver cirrhosis
目的：观察恩替卡韦分散片治疗乙型肝炎肝硬化的效果和安全性。方法：对100例乙型肝炎肝硬化患者进行随机对照试验，按1∶1的比例抽签分为观察组和对照组，观察组50例患者服用恩替卡韦分散片，对照组50例患者服用恩替卡韦片，观察治疗前后患者乙型肝炎病毒脱氧核糖核酸（ HBV-DNA）阴转情况及Child-Pugh评分的改变。结果：治疗12个月后，2组患者HBV-DNA对数值及肝脏Child-Pugh评分均较治疗前明显下降，差异均有统计学意义（P＜0.05），但组间差异无统计学意义（P＞0.05）；2组均未发现严重不良反应。结论：恩替卡韦分散片在治疗乙型肝炎肝硬化方面具有显著的抗病毒作用，疗效与恩替卡韦片相当。
目的：觀察恩替卡韋分散片治療乙型肝炎肝硬化的效果和安全性。方法：對100例乙型肝炎肝硬化患者進行隨機對照試驗，按1∶1的比例抽籤分為觀察組和對照組，觀察組50例患者服用恩替卡韋分散片，對照組50例患者服用恩替卡韋片，觀察治療前後患者乙型肝炎病毒脫氧覈糖覈痠（ HBV-DNA）陰轉情況及Child-Pugh評分的改變。結果：治療12箇月後，2組患者HBV-DNA對數值及肝髒Child-Pugh評分均較治療前明顯下降，差異均有統計學意義（P＜0.05），但組間差異無統計學意義（P＞0.05）；2組均未髮現嚴重不良反應。結論：恩替卡韋分散片在治療乙型肝炎肝硬化方麵具有顯著的抗病毒作用，療效與恩替卡韋片相噹。
목적：관찰은체잡위분산편치료을형간염간경화적효과화안전성。방법：대100례을형간염간경화환자진행수궤대조시험，안1∶1적비례추첨분위관찰조화대조조，관찰조50례환자복용은체잡위분산편，대조조50례환자복용은체잡위편，관찰치료전후환자을형간염병독탈양핵당핵산（ HBV-DNA）음전정황급Child-Pugh평분적개변。결과：치료12개월후，2조환자HBV-DNA대수치급간장Child-Pugh평분균교치료전명현하강，차이균유통계학의의（P＜0.05），단조간차이무통계학의의（P＞0.05）；2조균미발현엄중불량반응。결론：은체잡위분산편재치료을형간염간경화방면구유현저적항병독작용，료효여은체잡위편상당。
OBJECTIVE:To evaluate the efficacy and safety of entecavir dispersible tablet for hepatitis B cirrhosis. METHODS:A double blind randomized controlled trial was carried out on a total of 100 patients with hepatitis B liver cirrhosis,according to the proportion of 1∶1 draw randomly into observation group and control group, with 50 cases assigned to the observation group ( taking entecavir dispersible tablet ) and another 50 to the control group ( taking entecavir tablet) .The negative-return of HBV-DNA and Child-Pugh grading scores in the two groups were followed. RESULTS:After 12-months’ treatment, the logarithm value of HBV-DNA and liver Child-Pugh grading scores in both of the two groups were significantly reduced as compared before treatment, and the differences were statistically significant ( P <0.05 ); however, no statistically significant differences were noted between the two groups ( P >0.05 );the two groups were no serious adverse reaction.CONCLUSIONS:Entecavir dispersible tablet has remarkable antiviral effect in the treatment of hepatitis B liver cirrhosis.
